- Healthcare Professionals
- Research and insights
- Publications
- Recurrent Prostate Cancer
2021-02-02T00:00:00.000+08:00
Recurrent Prostate Cancer
Recurrent Prostate Cancer
Appl Radiol, volume: Jul/Aug, pages 40-43
Theranostics
Written by
Lenzo Nat, BSc BMedSci(Hons) MBBS MSc(Oncol) MMed MHSvMgt EMBA FRACP FAANMS GAICD
Lenzo Nat, BSc BMedSci(Hons) MBBS MSc(Oncol) MMed MHSvMgt EMBA FRACP FAANMS GAICD:::https://www.genesiscare.com/au/our-doctors/prof-nat-lenzo/
Lim Tee, MBBS, FRANCR
Lim Tee, MBBS, FRANCR:::https://www.genesiscare.com/au/our-doctors/dr-tee-lim/
Sohi J.S
Sohi J.S:::
Contrary to declining death rates for many common cancers, prostate cancer deaths are rising, with an increase of 5 percent from 2019 to 2020.1 Although most primary prostate cancer cases can be managed with radiotherapy or radical prostatectomy, 40 percent of men treated for this cancer will have disease relapse,2 with castration-resistant prostate cancer accounting for most deaths.3 68Ga PSMA-11 PET/CT suggests better sensitivity to low levels of PSA,4 and the ability to identify the location of disease recurrence after radical prostatectomy in half of the patients with a PSA level between 0.5 and 1 ng/ml,5,6 as demonstrated in this case study.